BiOptix Diagnostics Inc., a Boulder, Colo.-based developer of a biomolecule detection system, has raised $3 million in Series A funding. Boulder Ventures led the round, and was joined by individual angels.
BiOptix Diagnostics, Inc., a Boulder, CO based analytical instrumentation firm, announced today the closing of $3M Series A financing. The $3M round was led by Boulder Ventures Ltd. and includes several private investors.
“The disruptive innovation of Nobel Laureate Dr. Jan Hall teaming with scientists at BiOptix provides the company with unsurpassed analytical performance,” said Kyle Lefkoff, Managing Partner of Boulder Ventures. “This is another example of the University of Colorado’s contribution to stimulating innovation in the local business community. We believe that the BiOptix solution will have a significant impact in pharmaceutical applications and molecular diagnostics.”
In conjunction with the financing, Richard Whitcomb has been appointed President and CEO. Whitcomb was previously President and COO. Dr. Misha Plam, the Founder of BiOptix and former founder and CEO of Sievers Instruments, continues as a Director and key advisor to the company.
“This investment represents the next phase in the history of the company,” said Whitcomb. “It enables us to move our proven technology into commercialization and develop applications that help our customers improve quality, productivity and time to market.”
About BiOptix: BiOptix has developed an array-based biomolecule detection system that addresses many markets that currently cannot obtain the needed sensitivity and throughput in a single solution. Entry markets include biopharma and low molecular drug development, kinetic analyses, antibody development and quality control and process analysis. The technology has been evaluated in multiple biomolecular systems and chemistries, including proteins, DNA, glycans and whole pathogens.